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 An adenoviral vector (Ad) expressing a Wnt decoy receptor (sLRP6E1E2) is known to 
induce an anti-fibrotic effect by inhibiting Wnt signaling. We evaluated its effects in vivo 
using pig models and attempted to introduce an alginate gel-matrix system to prolong the 
effect of the Ad. Transduction efficiency was compared by fluorescent micrographs for the 
comparison of biological activity of Ad in different form; naked, gel-released and Ad in 
dissolved gel. And then, 50 days after the formation of full-thickness skin defects on the backs 
of Yorkshire pigs, scars were divided into five treatment groups: I, control, II, alginate gel, III, 
alginate gel capsulated control, IV, naked LRP6, and V, alginate gel capsulated LRP6. To 
evaluate its therapeutic efficacy, scar size and color index were compared, and various factors 
influencing scar formation and collagen rearrangement were analyzed through histology, 
immunohistochemistry and immunofluorescence assay. Real-time reverse transcriptase-
polymerase chain reaction (RT-PCR) was also analyzed for evaluation of expression levels of 
TGF-β1, TGF-β3, MMP-1, TIMP1, and α-SMA mRNAs. And to examine inflammatory cell 
infiltration within the scar tissues, the number of inflammatory cells was calculated from four 
serial H&E-stained tissue sections. 
2 
 GFP expression from gel-released Ad and Ad in dissolved gel was much higher than naked 
Ad. The size and color index of the scars has improved for the Ad treated group in pig model. 
The alginate gel encapsulating dE1-k35/sLRP6E1E2 treated scars (group V) were 
significantly improved in terms of scar surface size, erythema and melanin indices compared 
to other groups. Masson’s trichrome stain showed that premature collagen deposition was 
markedly decreased in group V scar tissues compared to the other groups. Picrosirius red stain 
also revealed that sLRP6E1E2 induces collagen rearrangement to resemble that of mature, 
bundle-shaped collagen fibers, and gel encapsulation enhances its efficacy. Expression levels 
of the major ECM components; collagen I, elastin, and fibronectin, are significantly decreased 
by sLRP6E1E2 overexpression, especially in the alginate gel reservoir. And the alginate gel 
encapsulating dE1-k35/sLRP6E1E2-treated scar tissues (group V) showed decreased TGF-β1 
mRNA expression and increased TGF-β3 mRNA expression compared with other groups. 
The treatment also increases matrix metalloproteinase-1 mRNA expression and decreases 
tissue inhibitor of metalloproteinases-1 and alpha-smooth muscle actin mRNA expression in 
pig scar tissues. And Alginate gel encapsulating dE1-k35/sLRP6E1E2 decreases 
inflammatory cell counts and mast cell counts in pig scar tissues.  
 Decoy Wnt receptor (sLRP6E1E2)-expressing adenovirus treatment improved scar quality in 
a pig model. Loading this construct in alginate gel allows sustained virus release into local 
tissues and prolongs Ad activity, thus maintaining its therapeutic effect longer in vivo. These 
advantages of the Ad/alginate system could markedly augment scar remodeling effects of 




key words : gene therapy, adenovirus, scar, alginate gel, decoy Wnt receptor, pig model 
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I. INTRODUCTION  
 
 Some wounds undergo abnormal healing process and leave disfiguring scars. Hypertrophic 
scars and keloids are representative examples of healed skin that is exceptionally red, thick, 
protruded, and tight. Various mechanisms have been proposed to explain keloid pathogenesis, 
but, treatment of keloids is extremely difficult as keloids frequently form at the site of injury, 
recur after excision, and always overgrow beyond the boundaries of original wound. These 
abnormal scarring is usually the result of unbalanced collagen production and degradation. 
Chronic, persistent, and prolonged proliferation of fibroblast leads to excessive synthesis and 
deposition of extracellular matrix (ECM) components, especially collagen. Although patients 
usually suffer from aesthetic disturbances and functional problems, these scars are difficult to 
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treat due to their complex pathophysiology and unknown polygenetic precipitating factors1-3. 
The response to treatment among patients is highly variable, and currently available therapies 
often achieve only temporary improvement.1,4,5 
Transforming growth factor-β (TGF-β) is a key regulator of fibroblast activation that drives 
the excessive synthesis of ECM in fibrotic diseases. Recently, signaling cross-talk between the 
Wnt/β-catenin, TGF-β1, and Smads are demonstrated, where Wnt/β-catenin signaling 
activates TGF-β1 and TGF-β1 promotes Wnt/β-catenin signaling. Therefore, inhibition of the 
canonical Wnt pathway can be an effective approach to target TGF-β1 signaling which both 
can synergistically downregulate fibrogenesis. Therefore, on our previous research, we have 
demonstrated that soluble Wnt decoy receptor of LRP6 (sLRP6E1E2)-expressing Ad (dE1-
k35/sLRP6E1E2), which expresses LRP6’ E1 and E2 domain, prevents Wnt-mediated 
stabilization of cytoplasmic β-catenin and decreases Wnt/β-catenin signaling, and this 
construct can degrade extracellular matrix in HDFs, KFs, and primary keloid spheroids, and 
thus it may be beneficial for treatment of keloids6. 
 Although adenoviral vectors are popular for gene therapy due to their high gene-transfer 
efficiency, they can deteriorate rapidly within a few weeks due to a short half-life, enzymatic 
inactivation, and transient effects. This may require repeated administration of an adenovirus 
to generate the desired anti-fibrotic effect, and regional administration of a high concentration 
of Ad can impair potential therapeutic effect and decrease safety. To deal with these problems, 
we loaded the virus in a sodium alginate-based hydrogel, which is a natural polymer 
frequently used in biomedical applications7-9. Alginate gel can be used as a depot system for 
the sustained release of Ad and maintaining Ad viral activity without affecting its biological 
activity7,8. Also, on previous researches, we examined that the use of alginate gel could 
increase therapeutic efficacy of adenovirus in a pig scar model10. 
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 In this study, we investigated the anti-fibrotic and scar remodeling effect of decoy Wnt 
receptor (sLRP6E1E2)-expressing adenovirus in vivo animal model. And we also demonstrate 
the use of an alginate gel-matrix system as a delivery vehicle to entrap sLRP6E1E2-
expressing Ad for sustained release to promote scar tissue remodeling in a pig model. 
 
II. MATERIAL AND METHODS 
1. Preparation of Ad and alginate gel 
A replication-incompetent Ad expressing the Wnt decoy receptor (dE1-k35/sLRP6E1E2) and 
control Ad (dE1-k35/LacZ)11 were used in this study. The propagation, purification, and 
titration of Ad were performed as previously described12,13 . An alginate (alginic acid sodium 
salt, Sigma, St. Louis, MO) solution of 5 wt% was prepared with 0.5 g alginate and 0.09 g 
NaCl (Sigma) in 10 ml phosphate-buffered saline (PBS). The alginate solution was stirred for 
24 h at room temperature and gelated in 50 mM CaCl2 (Sigma)7. 
2. Biological activity of encapsulated Ad 
To compare the biological activity of Ad in different forms, Ad (1×1010 VP of dE1/GFP) was 
encapsulated in 5% alginate gel, and incubated with Dulbecco’s modified Eagle’s medium at 
37°C for 1, 3, 5, 7, 9 and 11 days. At each time point, medium that containing the released Ad 
was collected (gel-released Ad), and the remaining Ad/alginate gel was dissolved (Ad in 
dissolved gel). SK-Hep 1 cells were then transduced with naked Ad, gel-released Ad, and Ad 
in dissolved gel. Transduction efficiency was compared in fluorescent micrographs showing 
SK-Hep1 cells incubated with Ad in each form. 
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3. Scar formation 
Female Yorkshire pigs (4 months of age, 40 kg) were used for the scar model. This animal 
study was approved by an institutional review board of Yonsei university. All animal 
experimental procedures were performed in accordance with the relevant guidelines and 
regulations of the Department of Laboratory Animal Resources, Yonsei Biomedical Research 
Institute, Yonsei University College of Medicine. Anesthesia was induced in each pig via 
intramuscular injection of Zoletil®  (5 mg/kg, Virbac, Carros, France) and Rompun®  (2 mg/kg, 
Bayer, Seoul, Korea) and maintained through inhalation of isoflurane (IsoFlo® , Abbott 
Laboratories, Abbott Park, Illinois). After complete hair removal, 36 full-thickness skin 
defects (3×3cm2) were created symmetrically on the back of each Yorkshire pig, with 18 
wounds on each side of the midline. The wound was spaced at least 3cm apart and reached the 
depth of the muscle fascia to mimic human scar formation. Intravenous antibiotics were 
administered, and TegaDerm®  (3M, St Paul, MN) was used as wound dressing for 5 days. Scar 
tissues, which were distinct in appearance compared to the peripheral normal tissues, were 
formed 50 days after creating the initial skin defects. 
4. Injection of Ad 
Wound epithelialization and scar formation occurred on postoperative day 50. Scars were 
divided into five treatment groups: I, PBS (control, n=7); II, alginate gel (gel, n=7); III, 
alginate gel encapsulating dE1-k35/LacZ (gel+dE1-k35/LacZ, capsulated control, n=7); IV, 
naked dE1-k35/sLRP6E1E2 (naked LRP6, n=7); and V, alginate gel encapsulating naked dE1-
k35/sLRP6E1E2 (gel+dE1-k35/sLRP6E1E2, capsulated LRP6, n=8) (5×107 PFU). Under 
anesthesia, viruses were injected with a 27-gauge needle with 1-ml syringe, and Ad/alginate 
gel mixtures were directly injected into the intradermal layers of the scar regions.  
5. Therapeutic evaluation of scar size and erythema and melanin indices 
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The surface areas of the scars were imaged with a digital camera. The images were 
measured with a ruler and compared to a 1 cm2 standard, and measurements were assessed 
with ImageJ software (National Institutes of Health, Bethesda, MD, USA). Scar color was 
quantitatively analyzed with a spectrophotometer (CM-700D; KONICA MINOLTA, INC., 
Tokyo, Japan). The color of each scar was examined with erythema (the degree of scar 
redness) and melanin (the degree of scar darkness) indices14. Each value was measured at least 
three times, and the mean was calculated. All of the evaluations were performed every 10 days 
until the 50th day after virus injection. We normalized the values of alginate gel (gel), alginate 
gel encapsulating dE1-k35/LacZ (capsulated control), naked dE1-k35/sLRP6E1E2 (naked 
LRP6), and alginate gel encapsulating dE1-k35/sLRP6E1E2 (capsulated LRP6)-treated scars 
to that of PBS-treated scars. 
6. Histology and immunohistochemistry 
Representative sections were stained with hematoxylin & eosin (H&E) and Masson’s 
trichrome before examination under light microscopy. Scar tissue sections were incubated at 
4°C overnight with one of the following primary antibodies: mouse anti-collagen type-I 
(ab6308; Abcam, Ltd., Cambridge, UK), mouse anti-elastin (E4013; Sigma-Aldrich Co.), and 
mouse anti-fibronectin (sc-52331; Santa Cruz Biotechnology, Santa Cruz, USA). Then, tissues 
were incubated at room temperature for 20 minutes with the DAKO Envision™ Kit (DAKO, 
Glostrup, Denmark) as a secondary antibody. Diaminobenzidine/hydrogen peroxidase (DAKO) 
was used as the chromogen substrate. All sections were counterstained with Meyer’s 
hematoxylin. Expression levels of type I collagens, elastin, and fibronectin were semi-
quantitatively analyzed with MetaMorph®  image analysis software (Molecular Devices, 
Sunnyvale, CA, USA). Values are calculated as the mean optical density of six different 
digital images. Immunohistochemistry was performed by the same individual who was 
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blinded to the experimental group, and the tissue sections for analysis were obtained from the 
center areas of scar tissue. 
Picrosirius red (Sigma-Aldrich Co.) staining was performed on specimens collected 5 or 50 
days after experiments for evaluation of collagen-fiber arrangement with optical microscopy 
(BX51, Olympus, Tokyo, Japan) at ×200 magnification. 
7. Immunofluorescence assay 
Specimens were collected 5 and 50 days after treatment and were embedded in paraffin 
blocks. Paraffin-embedded tissues were sectioned, deparaffinized, rehydrated, and treated 
with blocking buffer (5% normal goat serum, S-100, Vector Laboratories Inc., Burlingame, 
CA, USA) for 1 hour. After removing the blocking buffer, sections were immersed in primary 
antibody (anti-Flag, Sigma) overnight at 4°C and then incubated in secondary antibody (rabbit 
anti-mouse FITC, Santa Cruz Biotechnology) at room temperature for 2 hours. Anti-Flag 
antibody was used to confirm the Flag-tagged LRP6. Confocal microscopy (LSM700, Carl 
Zeiss, Oberkochen, Germany) was performed on tissues were mounted on slides using 
Vectashield®  mounting medium containing the nuclear stain DAPI (Vector Laboratories). 
 
8. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for expression 
levels of TGF-β1, TGF-β3, MMP-1, TIMP1, and α-SMA mRNAs 
At 50 days after Ad injection, total RNA was prepared from tissue with TRIzol®  reagent 
(Invitrogen, Carlsbad, CA, USA), and complementary DNA was prepared from 500 ng total 
RNA by Oligo dT (Bioneer Corp., Alameda, CA, USA) and a cDNA synthesis kit (Bioneer 
Corp.), under the following conditions: 42°C for 60 min, 94°C 5 min. Real-time PCR was 
performed with an StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific, 
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Waltham, MA, USA) and following a Taqman®  Real-time PCR assay (Thermo Fisher 
Scientific) [assay ID: Ss03382325_u1 (TGF-β1), Ss03394349_g1 (TGF-β3), Ss04245657_g1 
(matrix metalloproteinase-1, MMP-1), Ss03381944_u1 (tissue inhibitor of metalloproteinase 1, 
TIMP-1), and Ss04245588_m1 (α-smooth muscle actin, α-SMA)]. Target mRNA expression 
levels were normalized to that of β-actin (Thermo Fisher Scientific) [assay ID: 
Ss03376563_uH] levels, and relative quantization was expressed as fold-induction compared 
with control conditions in each tissue. PCR was performed three times for each mRNA in 
each tissue, and the average value was calculated. 
9. Statistics 
Results are expressed as the mean ± standard deviation (SD). Data were analyzed with 
repeated-measures one-way analysis of variance (ANOVA). Two sets of independent sample 
data were compared using paired t-tests; p<0.05 was considered statistically significant. 
 
III. RESULTS 
1. Ad is continuously released from the alginate gel, and gel encapsulation prolongs Ad 
biological activity 
 Transduction efficiency was compared by fluorescent micrographs showing SK-Hep1 cells 
incubated with Ad in different forms (Figure 1). GFP expression of naked Ad was noticeably 
decreased from the 3rd day of incubation and almost absent after the 7th day (Figure 1 upper 
low), whereas cells transduced with 5% gel-released Ad showed relatively strong and 
sustained GFP expression until the 11th day (Figure 1 middle low). Also, GFP expression of 
Ad in dissolved gel was prolonged and much higher than naked Ad (Figure 1 lower low). 
These results demonstrate that the alginate gel provides a biocompatible environment for Ad 




Figure 1. Comparisons of GFP expression level in each group. Fluorescent microscopies 
showing SK-Hep1 cells incubated with Ad in various forms. Ad (1x1010 VP of dE1/GFP) was 
encapsulated in 5% alginate gel, and incubated with Dulbecco’s modified Eagle’s medium at 
37℃ for 1, 3, 5, 7, 9, 11, and 13 days. SK-Hep1 cells transduced with dE1/GFP (naked Ad, 
top row), released Ad from 5% gel (middle row), and dissolved Ad-gel (lower row). GFP 
expression from gel-released Ad and Ad in dissolved gel was much higher than naked Ad, 
demonstrates that the alginate gel provides a biocompatible environment for sustained release 
of Ad and maintenance of Ad viral activity. 
 
We also examined sLRP6E1E2 expression by immunofluorescence staining of pig scar 
tissues. The alginate gel encapsulating dE1-k35/sLRP6E1E2 treated group (group V) showed 
markedly increased immune reactivity for sLRP6E1E2 compared to the other groups, 
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especially group IV 5 days after injection (Figure 2(a)), and persistent sLRP6E1E2 expression 
was observed 50 days after injection (Figure 2(b)). More importantly, the total level of 
sLRP6E1E2 expression from alginate gel encapsulating dE1-k35/ sLRP6E1E2 was much 
higher than naked dE1-k35/sLRP6E1E2 both 5 and 50 days after injection. This shows the 
potential utility of alginate gel encapsulating dE1-k35/sLRP6E1E2 for in vivo applications 
that require long-term and efficient gene transfer. 
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Figure 2. Immunofluorescence staining of pig scar tissues. (a) 200x. sLRP6E1E2 
expression by immunofluorescence staining in pig scar tissues, 5th day after injection. The 
alginate gel encapsulating dE1-k35/sLRP6E1E2 treated group (Group V) showed markedly 
increased immune-reactivity.; (b)200x. sLRP6E1E2 expression by immunofluorescence 
staining in pig scar tissues, 50 days after injection. Group V showed persistent sLRP6E1E2 
expression. The total level of sLRP6E1E2 expression from Group V was much higher than 
group IV, indicating the potential utility of gel encapsulation for long-term and efficient gene 
transfer. 
2. sLRP6E1E2-expressing Ad/gel decreases scar size and color in pig scar tissue. 
 The therapeutic effect of sLRP6E1E2-expressing Ad on scar tissue was evaluated with scar 
size and erythema and melanin indices (Figure 3 and 4). The values listed below correspond to 
the following treatment groups: I, PBS (control); II, alginate gel (gel); III, alginate gel 
encapsulating dE1-k35/LacZ (gel+dE1-k35/LacZ; capsulated control); IV, naked dE1-
k35/sLRP6E1E2 (naked LRP6); and V, alginate gel encapsulating naked dE1-k35/sLRP6E1E2 
(gel+dE1-k35/sLRP6E1E2, capsulated LRP6). On the photographic evaluation on initial and 
50 days after treatments, the scar areas decreased, and the color improved at 50 days after the 
injection of alginate gel encapsulating naked dE1-k35/sLRP6E1E2 (Group V) (Figure 3). 
Photographs of scars were taken before and after each treatment were taken and measured 
with Image J software.  
 The sizes of initial scars were measured as 1.46 ± 0.88 cm2, 1.51 ± 0.79 cm2, 1.21 ± 0.15 cm2, 
1.15 ± 0.18 cm2, and 1.42 ± 0.3 cm2 in each group, respectively, and there were  statistically 
no differences. However, the sizes of the scars decreased to 1.14 ± 0.48 cm2 (78% of initial 
scar, p<0.05), 0.81 ± 0.08 cm2 (78% of initial scar, p<0.05), 0.96 ± 0.11 cm2 (79% of initial 
scar, p<0.05), 0.81 ± 0.17 cm2 (70% of initial scar, p<0.05), and 0.87 ± 0.19 cm2 (61% of 
initial scar, p<0.01), respectively, by the 50th day after treatments, indicating that sLRP6E1E2 
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expression from Ad (groups IV and V) reduces scar size. Furthermore, alginate gel 
encapsulating dE1-k35/sLRP6E1E2 treated scars (group V) were only significantly reduced 
compared to control or scars treated with capsulated control virus (p<0.05, Figure 3 & 4, left).  
 The erythema indices of the initial scars were 2.9 ± 0.54, 3.12 ± 0.91, 2.77 ± 0.5, 2.32 ± 0.19, 
and 3.02 ± 0.48 in each group, respectively. Erythema was significantly decreased to 2.76 ± 
0.55, 2.29 ± 0.43, 2.15 ± 0.32, 1.99 ± 0.39, and 1.88 ± 0.12 in each group, respectively, by the 
50th day after treatments. Compared to baseline, the ratio of erythema indices at 50 days 
treated with PBS, gel, capsulated control, naked LRP6, and capsulated LRP6 were 92%, 88%, 
66%, 80%, and 59% (p<0.01) in each group, respectively. The alginate gel encapsulating dE1-
k35/sLRP6E1E2 treated scars (group V) were significantly improved in terms of erythema 
compared to other groups (p<0.05; Figure 4, middle). Similarly, the melanin indices at 50 
days were significantly reduced by 75%, 54%, 60%, 70%, and 5% (p<0.01) in each groups, 
respectively, showing that sLRP6E1E2 expression from gel-encapsulated Ad (group V) 
reduces the melanin indices of scars (p<0.05 vs. groups I to IV; Figure 4, right). Taken 
together, these results indicate that sLRP6E1E2-expressing Ad plays a prominent role in 
reducing scar size, erythema, and pigmentation. Notably, Ad in an alginate gel-matrix system 
showed more effective biologic activities than naked Ad.  
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Figure 3. Photographic analysis of scar tissues. The photographs of scars before and 50 
days after treatment in pigs of each group (Groups: I, PBS (control); II, alginate gel (gel); III, 
alginate gel encapsulating dE1-k35/LacZ (gel+dE1-k35/LacZ; capsulated control); IV, naked 
dE1-k35/sLRP6E1E2 (naked LRP6); and V, alginate gel encapsulating naked dE1-
k35/sLRP6E1E2 (gel+dE1-k35/sLRP6E1E2, capsulated LRP6). 
 
Figure 4. Therapeutic evaluation of scar area, color index, and pliability with Image J 
software and spectrophotometry. Therapeutic evaluation of the scars sLRP6E1E2-
expressing Ad plays a prominent role in reduction of scar surface area and color (mainly 
composed of erythema and melanin). Ad with alginate gel-matrix system showed more 
effective biologic activities than naked Ad. Data are expressed as a mean±standard error of the 
mean. 
3. sLRP6E1E2-expressing Ad/gel induces collagen rearrangement  
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 Masson’s trichrome stain was performed to evaluate the effects of sLRP6E1E2-expressing 
Ad on collagen-fiber arrangement. From the 5th day after treatments, premature collagens 
were deposited on scar tissues, but in group V, premature collagen deposition area was smaller 
than other groups (Figure 5a). However, on the 50th day after treatment, Masson’s trichrome 
stain revealed that premature collagen deposition was markedly decreased in group V scar 
tissues (alginate gel encapsulating dE1-k35/sLRP6E1E2) compared to the other groups 





Figure 5. sLRP6E1E2-expressing Ad/gel induces collagen rearrangement. Masson’s 
trichrome stain was performed to evaluate the effects of sLRP6E1E2-expressing Ad on 
collagen-fiber arrangement on the 5th (a) and 50th day (b) after treatments. Premature collagen 
deposition was markedly decreased in group V scar tissues (alginate gel encapsulating dE1-
k35/sLRP6E1E2) compared to the other groups. original magnification, ×12. 
 
 Tissues were also stained with picrosirius red, which specifically binds collagen fibrils of 
various diameters. On the 50th day after treatment, premature collagen depositions were 
displaced by mature and well-arranged collagen bundles, and dense and coarse collagen 
bundles structure were replaced by thin and shallow collagen bundles. Furthermore, scar 
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tissues in groups IV and V had closely packed collagen fibers and formed complete bundles 
compared to other groups (groups I to III), which is similar to normal dermal structure (Figure 
6). These data suggested that sLRP6E1E2 induces collagen rearrangement to resemble that of 
mature, bundle-shaped collagen fibers, and gel encapsulation enhances its efficacy. 
 
Figure 6. Picrosirius red staining in a pig scar tissues. On the 50th day after treatment, 
premature collagen depositions were displaced by mature and well-arranged collagen bundles, 
and scar tissues in groups IV and V had closely packed collagen fibers and formed complete 
bundles compared to other groups (groups I to III), which is similar to normal dermal 
structure. 
4. sLRP6E1E2-expressing Ad/gel reduces collagen I, elastin, and fibronectin  
 We examined the effects of sLRP6E1E2 overexpression on the major ECM components of 
scar tissues. Immunohistochemical staining of scar sections revealed significant reductions in 
type I collagen and fibronectin in the alginate gel encapsulating dE1-k35/sLRP6E1E2-treated 
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group (group V) compared with other groups (**p<0.01, Figure 7). Reductions of elastin in 
naked dE1-k35/sLRP6E1E2-treated scar tissues (group IV) were significant compared to scars 
in groups I, II, and III, but smaller than that of group V. Taken together, these data strongly 
suggest that expression levels of the major ECM components are significantly decreased by 










Figure 7. Immunohistochemical staining for collagen type-I, elastin, and fibronectin in 
pig scar tissues at 50th day after treatment (a) and semi-quantitative images analysis with 
MetaMorph®  (b). The expression levels of the major extracellular matrix components type-I 
collagen, elastin, and fibronectin were lower in scar tissues treated with the alginate gel 
encapsulating group V compared with other groups, especially compared with group IV. 
(H&E, X 400, others, X200) 
 
5. Alginate gel encapsulating dE1-k35/sLRP6E1E2 downregulates TGF-β1 and 
upregulates TGF-β3 mRNA expression in pig scar tissues  
To examine the mechanism by which sLRP6E1E2-expressing Ad suppresses expression of 
the major ECM components in pig scar tissues, the change of TGF-β1 and TGF-β3 mRNA 
levels were evaluated on various groups by qRT-PCR. The alginate gel encapsulating dE1-
k35/sLRP6E1E2-treated scar tissues (group V) showed decreased TGF-β1 mRNA expression 
and increased TGF-β3 mRNA expression compared with other groups (Figure 8). The TGF-
β1 mRNA level of scar tissues from group V (Figure 8a) were 5- and 3-fold lower than that of 
groups I and IV, respectively (both **p < 0.001). In addition, TGF-β3 mRNA levels of group 
V (Figure 8b) were 1.6-fold higher compared to group I and 1.8-fold higher compared to 
group IV (both p < 0.001). These results suggest that the reduced expression of ECM 
components by sLRP6E1E2 overexpression is associated with decreased TGF-β1 expression 
and increased TGF-β3 expression.  
Scar remodeling-associated molecules such as MMP-1, TIMP-1, and α-SMA are important 
markers of the effects of TGF-β on wound repair. Therefore, we performed qRT-PCR analysis 
of MMP-1, TIMP-1, and α-SMA and showed differential expression of these matrix 
remodeling-associated molecules among experimental groups. MMP-1 expression levels of 
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group V scar tissues were significantly increased by 4.9- and 1.7-fold, respectively, versus 
those of groups I and IV scar tissues (both p<0.001, Figure 9(a)). In contrast, TIMP-1 and α-
SMA expression levels of group V scar tissues were significantly decreased by 2.2- and 2.8-
fold, respectively, compared to groups I and II (both p<0.01, Figure 9(b,c)). However, there 
was no significant difference between groups IV and V. These results suggest that 
sLRP6E1E2 upregulates MMP-1 and downregulates TIMP-1 and α-SMA, which are major 
players in collagen breakdown. 
 
 
































































(a)                                             (b)            
 
Figure 8. Alginate gel encapsulating dE1-k35/sLRP6E1E2 downregulates TGF-β1 and 
upregulates TGF-β3 mRNA expression in pig scar tissues. (a) TGF-β1 mRNA levels of 
group V were 5-fold lower than that of group I and 3-fold lower than that of group IV scar 
tissues. (b) TGF-β3 mRNA levels of group V were 1.6-fold higher than that of group I scar 
tissues and 1.8-fold higher than that of group IV scar tissues.  
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Figure 9. Alginate gel encapsulating dE1-k35/sLRP6E1E2 increases MMP-1 mRNA 
expression and decreases TIMP-1 and α-SMA mRNA expression in pig scar tissues (a) 
MMP-1 expression levels of group V scar tissues were significantly increased by 4.9- and 1.7-
fold versus groups I and IV scar tissues, respectively (***p<0.001). In contrast, TIMP-1(b) 
and α-SMA expression(c) levels of group V scar tissues were significantly decreased by 2.2- 
and 2.8-fold versus group I scar tissues, respectively (*p <0.05, ** p <0.01, ***p < 0.001). 
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6. Alginate gel encapsulating dE1-k35/sLRP6E1E2 decreases inflammatory cell counts 
and mast cell counts in pig scar tissues  
 To examine inflammatory cell infiltration within the scar tissues, the number of inflammatory 
cells was calculated from four serial H&E-stained tissue sections. On day 5 of the 
postoperative period, the mean numbers of inflammatory cells within the scar tissue were 
9.2±2.39, 9.25±2.63, 5.80±1.79, 7.75±1.71, and 2.20±1.30 in each groups, respectively. On 
day 50 of the postoperative period, these were 9±2.6, 8.5±1.41, 8±1.01, 6.28±0.84, and 
3.35±0.30 in each groups, respectively. The numbers of inflammatory cells on Days 5 and 50 
were significantly lower in the alginate gel encapsulating dE1-k35/sLRP6E1E2-treated scar 
tissues (group V) (* p < 0.05). 
  Mast cells are reported to be involved in the proliferation and contraction of fibroblasts, and 
the synthesis of ECM. They also play a key role in scar formation. On day 50 of the 
postoperative period, the mean numbers of mast cells were 10.17±0.6, 8.97±0.39, 8.53±0.52, 
7.03±0.38, and 2.51±0.25 in each groups, respectively. A statistically significant decrease was 
seen in the mean number of mast cells in the alginate gel encapsulating dE1-k35/sLRP6E1E2-
treated scar tissues (group V) in comparison of other groups (* p < 0.05). 
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Figure 10. Inflammatory cell and mast cell count in pig scar tissue. (a) Inflammatory cell 
(black arrow) infiltration, as demonstrated by H&E staining (magnification, 400×) and mast 
cell (white arrow head) count with toluidine blue staining in the scar area. (b and c) The 
numbers of inflammatory cells on Days 5 and 50 were significantly lower in the alginate gel 
encapsulating dE1-k35/sLRP6E1E2-treated scar tissues (group V) (* p < 0.05). (d) The 
numbers of mast cells on Days 50 were significantly lower in the alginate gel encapsulating 
dE1-k35/sLRP6E1E2-treated scar tissues (group V) compared with other groups (* p < 0.05). 
 
IV. DISCUSSION 
 Keloids are benign fibroproliferative scars that invade into surrounding normal skin beyond 
the original wound boundaries and keep growing slowly like a benign skin tumor4. The 
incidence has been reported about 16%15, and they are highly associated with dark pigmented 
skin16. Unlike hypertrophic scars, they rarely regress spontaneously, resulting in both aesthetic 
problems and pain and functional disability.  
 Various mechanisms have been suggested to explain keloid pathogenesis; altered growth 
factor regulation, immune dysfunction, aberrant collagen turnover, sebum or sebocytes as 
self-antigens, altered mechanics, and altered apoptotic signaling in keloid fibroblasts1,17. 
Although a consistent theory is still lacking, TGF-β1 is known as a potent fibrogenic growth 
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factor that plays a primary role in keloid pathophysiology2,18,19. Thus, targeting TGF-β1 with 
pharmacologic interventions represents an attractive therapeutic option. 
 Skin injury involves response of Wnt/β-catenin pathway, with a critical role in epidermal 
stem cell maintenance, hair follicle development, regeneration and fibroblast-mediated 
scarring20. Activation of Wnt pathway plays a profibrotic role in cutaneous wound healing. 
Wnt/β-catenin signaling can upregulate TGF-β expression 21,22, and TGF-β1 can promote β-
catenin signaling23-25. Furthermore, TGF-β stimulates canonical Wnt signaling by reducing the 
expression of the Wnt antagonist Dickkopf protein-126. Prolonged activation of Wnt/β-catenin 
signaling has been observed in human hyperplastic wounds27. Therefore, inhibition of the 
canonical Wnt pathway might be an effective approach to target TGF-β signaling in fibrotic 
diseases such as keloids or hypertrophic scars.  
 We previously generated a novel soluble decoy Wnt receptor, sLRP6E1E2, which is 
composed of the low-density lipoprotein receptor-related protein 6 (LRP6) E1 and E2 regions, 
for functional interaction with Wnt and sLRP6E1E2-expressing replication-incompetent 
adenovirus (dE1-k35/sLRP6E1E2). An adenovirus in which both the E1 and E2 genes have 
been deleted blocks DNA replication and neosynthesis of viral protein. E1 encodes a 
transcription trans-activator crucial for the expression of genes key to viral replication, and E2 
encodes a DNA-binding protein crucial for late gene transcriptional activation and viral 
replication11. As LRP6 plays a key role in activation of the canonical Wnt signaling pathway, 
these replication-defective Ad-based vectors engineered with the soluble decoy Wnt receptor 
sLRP6E1E2 induce an anti-fibrotic effect by inhibiting Wnt and TGF-β signaling. The effect 
was observed in vitro with human dermal fibroblasts and keloid spheroids in a previous study.  
 Using a pig scar model, we confirmed its therapeutic effect in vivo. Macroscopically, this 
approach helps to decrease scar size and minimize discoloration. Microscopically, we 
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observed that the collagen structure of scar tissue was become similar to normal tissue after 
treatment. Expression of structural proteins were decreased in treatment group. As in vitro 
results, sLRP6E1E2-expressing Ad downregulated TGF-β1 and upregulated TGF-β3 mRNA 
expression in vivo. In addition, expression of molecules that associated scar remodeling also 
convinced antifibrotic effect of sLRP6E1E2-expressing Ad. Expression level of MMP-1, 
which involves in the breakdown of extracellular matrix and tissue remodeling, breaking 
down the interstitial collagens, were increased in Ad-treated group. In contrast, TIMP-1, 
which has role in extracellular matrix remodeling by inhibitory activity of MMP-128,29, 
showed decreased expression level as well as α-SMA expression. The mast cells, known to be 
involved in the proliferation and contraction of fibroblasts, and the synthesis of ECM, which 
play a key role in scar formation, are also observed in fewer numbers in the virus-treated 
group. The numbers of inflammatory cells were lower in sLRP6E1E2-expressing Ad-treated 
group. Given that the keloid is the result of chronic inflammation of the reticula dermis30, this 
result is also expected to provide a positive basis for treating problem scarring in the future.   
 Although adenovirus is an attractive gene delivery vector with the advantages of high gene-
transfer ability, easy production/amplification, and low risk of insertional mutagenesis, its 
major drawback is rapid elimination of transduced cells16. As in vivo applications require 
long-term transduction, we introduced an Ad/alginate gel depot system. Previous studies 
indicated that the biological activity of Ad loaded in alginate gel is prolonged compared with 
that of naked Ad over an extended period of time7. And encapsulation of viral vectors may 
enhance therapeutic effect by masking viruses from clearance9. In this in vivo study, we 
confirmed that alginate gel-encapsulated decoy Wnt expressing Ad is more effective in scar 
management compared to naked Ad in a pig model. The alginate gel reservoir releases Ad in a 
sustained manner and maintains the biological activity of Ad longer. Alginate gel has also 
been shown to limit the Ad mobility by entrapping Ad within its scaffold, further minimizing 
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the spread of the replication-incompetent Ad outside the scar tissue. A microenvironment 




 Decoy Wnt receptor (sLRP6E1E2)-expressing adenovirus treatment improved scar quality in 
a pig model. Loading this construct in alginate gel allows sustained virus release into local 
tissues and prolongs Ad activity, thus maintaining its therapeutic effect longer in vivo. These 
advantages of the Ad/alginate system could markedly augment scar remodeling effects of 
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ABSTRACT (IN KOREAN) 
돼지 모델을 이용한 알긴산염 겔에 쌓인 Decoy Wnt 수용체 발현 
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최 세 운 
 
 Wnt decoy 수용체를 발현하는 아데노바이러스 벡터(Ad)는 Wnt 신호를 
억제하면서 항섬유화 효과를 나타낸다고 알려져 있다. 우리는 이의 in vivo 
효과를 돼지모델을 이용하여 확인하고, 알긴산염 겔 시스템을 이용하여 
Ad 의 효과를 더 길게 유지해보고자 하였다.  
 먼저 여러 형태의 Ad 의 생물학적의 유전자 전달 효과를 형광 현미경을 
이용하여 비교하였다. 그 다음은 요크셔 돼지의 등에 전층 피부 결손을 
만들고 50 일 후에 다섯 그룹으로 나누어 치료를 진행하였다. ( I, 대조군,  
II, 알긴산염, III, 알긴산염 겔로 쌓인 대조군, IV, naked LRP6, V, 알긴산염 
겔에 쌓인 LRP6) 이들의 치료 효과를 확인하기 위하여 흉터의 사이즈와 
멜라닌, 홍조 인덱스를 비교하였다. 또한 흉터 형성과 콜라겐섬유의 
재배열에 영향을 줄 수 있는 여러 요소들을 조직학, 면역화학적, 면역 
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형광학적으로 분석하였다. 또한 세포외기질을 구성하는 주요 구성원에 
대하여. RT-PCR 을 시행하고, 흉터 세포 내에 염증세포의 침윤 정도와 
염증세포의 수를 계산하였다.  
 GFP 발현 정도를 비교한 결과 겔 안의 Ad 에서 더 강하고 긴 발현 
정도를 나타내었다. 돼지 모델에서는 Ad 를 이용하여 치료한 그룹에서 
흉터의 크기와 색소 측면에서 더 좋은 효과를 나타내었고, 특히 겔로 쌓인 
Ad 로 치료한 그룹에서 통계적으로 유의한 효과를 나타내었다. 
 또한 조직 염색에서 그룹 V 의 조직은 미성숙한 콜라겐 침착이 유의하게 
줄었고 콜라겐이 정상과 비슷하게 재배열 됨이 관찰되었다. 세포외기질의 
주요 구성원인 1 형 콜라겐, 엘라스틴, 파이브로넥틴도 이 그룹에서 
유의하게 감소하였다. 또한 해당 그룹에서 TGF-β1 mRNA 의 발현이 
감소하고 TGF-β3 mRNA 의 발현이 증가하였으며 MMP-1 가 증가하고, 
TIMP, -SMA 는 감소하였다. 염증세포 및 비만세포의 수도 감소하였다.  
 Ad 를 알긴산염 겔과 결합시키는 것은 이 바이러스를 조직에 천천히 
방출하면서 그 효과를 오래 유지시키는 역할을 한다. 이를 이용하면  
Ad 의 독성을 최소화하면서 조직에 이를 높은 농도로 지속적으로 제공하여 
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